港股異動 | 創夢天地漲超12% 機構指自研遊戲提高盈利能力
格隆匯8月26日丨創夢天地(1119.HK)大幅拉昇漲超12%,現報5.21港元創一個半月新高,總市值74億港元。第一上海日前報吿指,公司發力自研遊戲,打造IP衍生品流量閉環第二增長曲線。該行給予公司目標價7.9港元,首次覆蓋予買入評級。據悉,創夢與騰訊聯合運營的《黑色沙漠》已於今年上線,該行認為公司未來預計將不斷通過自研遊戲提高公司的盈利能力。考慮到目前公司IP衍生品業務正在快速發展階段,市場空間潛力巨大。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.